`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`GUARDANT HEALTH, INC.
`Petitioner,
`v.
`UNIVERSITY OF WASHINGTON,
`Patent Owner.
`_____________________
`
`Case No. IPR2022-01116
`Patent No. 10,889,858
`_____________________
`
`PETITIONER’S EXPLANATION OF MULTIPLE PETITIONS
`CHALLENGING PATENT NO. 10,889,858
`AND RANKING OF PETITIONS
`
`
`
`
`
`
`
`
`
`
`
`
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent & Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`
`
`
`
`I.
`
`
`
`U.S. Patent No. 10,889,858
`
`Introduction
`Petitioner TwinStrand Biosciences is filing a second petition challenging the
`
`patentability of the claims of U.S. Patent Number 10,889,858. Pursuant to the
`
`Board’s July 2019 Trial Practice Guide Update, TwinStrand submits this paper to
`
`“identify: (1) a ranking of the petitions in the order in which it wishes the Board to
`
`consider the merits … , and (2) a succinct explanation of the differences between
`
`the petitions, why the issues addressed by the differences are material, and why the
`
`Board should exercise its discretion to institute additional petitions.”
`
`II. Ranking of the Petitions
`As explained below, the Board should institute on both Petitions. But, if the
`
`Board institutes on only one Petition, TwinStrand requests the Board institute
`
`IPR2022-01116 (“the Narayan Petition”).
`
`III. Succinct Explanation of Rationale for Multiple Petitions and the
`Differences Between the Petitions
`Mere days before Petitioner TwinStrand filed its first petition against
`
`Guardant’s challenged ’858 patent, Illumina (an unrelated third party) sued Patent
`
`Owner Guardant in district court, alleging that the ’858 patent’s inventorship is
`
`incorrect. Illumina alleged that an inventor named on the ’858 patent, who was
`
`formerly an Illumina employee, misappropriated Illumina trade secrets and
`
`breached his contracts with Illumina. Illumina further alleged that other Illumina
`
`employees contributed to the conception of the claimed inventions of the ’858
`
`1
`
`
`
`
`
`
`
`U.S. Patent No. 10,889,858
`
`patents and therefore should be named as inventors to the patent. EX1069, 19. The
`
`Illumina lawsuit casts significant doubt about whether the proper inventors are
`
`currently listed on the face of the ’858 patent. For example, inventors may be
`
`added or subtracted by settlement agreement at any time, or eventually by court
`
`order. Accordingly, there is a live, new dispute about the proper inventorship of the
`
`’858 patent.
`
`Additionally, about three weeks ago, and after Petitioner filed its first
`
`petition, the PTAB issued its decision in Incyte Corp. v. Concert Pharm., Inc.
`
`(PGR2021-00006), Paper 68 (May 11, 2022), which addressed the legal contours
`
`of the inventor disclosure exceptions of AIA § 102(b)(1). (Id. at 40). 35 U.S.C. §§
`
`102(b)(1)(B) and 102(b)(2)(B) provide for certain exceptions to AIA §102(a) prior
`
`art if the relied-upon subject matter in the prior art reference was publicly disclosed
`
`by the inventor, joint inventor, or someone who obtained the subject matter from
`
`the inventor, before the § 102(a) date of the prior art reference. In Incyte Corp., the
`
`Board, for the first time, articulated an analysis of the certain types of inventor
`
`disclosure exceptions of AIA § 102(b)(1). At the time it filed its first Petition,
`
`Petitioner could not have known of the PTAB’s opinion regarding inventor-
`
`publication exceptions.
`
`TwinStrand’s first petition for IPR of the ’858 patent in IPR2022-00747 (the
`
`Murtaza Petition), demonstrates that claims 1-29 are unpatentable as obvious over
`
`2
`
`
`
`
`
`
`
`U.S. Patent No. 10,889,858
`
`Murtaza, Schmitt, and Meyer (Ground 1) and further in view of Craig (Ground 2)
`
`or Kivioja (Ground 3). See IPR2022-00747, Paper 2, at 19-20. The petition relied
`
`on Murtaza, which has a publication date of May 2, 2013, approximately eight
`
`months before the earliest possible priority date of the ’858 patent.
`
`Petitioner is not aware of any public disclosures of the alleged invention by
`
`Guardant’s named inventors prior to Murtaza’s publication date of May 2, 2013.
`
`But the Illumina lawsuit has created significant uncertainty regarding whether the
`
`named inventors of the ’858 patent are, in fact, properly named, and whether issues
`
`of non-joinder of other proper inventors also exist. Naturally, these issues affect
`
`the possible scope of the inventor exceptions to §102(a) prior art, especially in
`
`light of the Incyte Corp. decision.
`
`Therefore, Petitioner files a second petition challenging the ’858 patent’s
`
`claims with similar grounds of unpatentability as the first petition, but relies on
`
`Narayan (EX1082) —which published on July 15, 2012, more than one year before
`
`the earliest possible priority date of the ’858 patent — instead of Murtaza
`
`(EX1004). No reference relied on in the Grounds of the Narayan Petition can fall
`
`under any exception to prior art under AIA § 102(b). Therefore, the second petition
`
`forecloses any argument from Patent Owner that an inventor-originated disclosure
`
`could except any reference in its Grounds. For this reason, if the Board were to
`
`institute only on one petition, TwinStrand requests that it be the Narayan petition.
`
`3
`
`
`
`
`
`
`
`U.S. Patent No. 10,889,858
`
`However, on the merits, both petitions should be instituted. As explained in
`
`the first petition, Murtaza explicitly discloses enriching cfDNA using hybrid
`
`capture techniques before sequencing specific cancer genes. And, as noted above,
`
`Petitioner is not aware of any disclosure of the subject matter of the reference that
`
`might cause it to fall under an exception to AIA § 102(b). Further, the Board has
`
`recognized that the potential to antedate a reference weighs in favor of instituting
`
`multiple petitions. Comcast Cable Commc’ns, LLC v. Veveo, Inc., No. IPR2019-
`
`00239, Paper 15 at 18 (P.T.A.B. July 5, 2019) (The Board was “persuaded that the
`
`potential to antedate a reference relied on in a Petition” weighs in favor of
`
`instituting two petitions.). Here, similar facts are in play.
`
`The second petition is filed more than a month before Patent Owner’s
`
`Preliminary Response is due, and therefore, Petitioner has no knowledge of Patent
`
`Owner’s strategy in defending its claims. Additionally, should the Board institute
`
`both Petitions, Petitioner will work to streamline these cases. For example,
`
`Petitioner would agree to a single deposition of witnesses for both cases. And
`
`Petitioner would agree to consolidate the case schedules as much as possible.
`
`Petitioner respectfully requests institution of both Petitions, or at least the Narayan
`
`Petition.
`
`
`
`
`
`4
`
`
`
`
`
`
`
`U.S. Patent No. 10,889,858
`
`IV. CONCLUSION
`Petitioner respectfully requests that the Board consider both petitions and
`
`institute both.
`
`
`
`
`
`
`Date: June 7, 2022
`1100 New York Avenue, NW
`Washington, DC 20005
`(202) 371-2600
`
`Respectfully submitted,
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`/R. Wilson Powers III/
`
`Ralph Wilson Powers III, Ph.D.
`Registration No. 63,504
`Lead Attorney for Petitioner
`
`5
`
`
`
`
`
`
`
`U.S. Patent No. 10,889,858
`
`CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e))
`
`The undersigned hereby certifies that the above-captioned PETITIONER’S
`
`EXPLANATION OF MULTIPLE PETITIONS CHALLENGING PATENT
`
`NO. 10,889,858 AND RANKING OF PETITIONS was served in its entirety on
`
`June 7, 2022, upon the following parties via FedEx® at the following addresses:
`
`Guardant Health / WSGR
` 650 Page Mill Road
`Palo Alto CA 94304
`Patent Owner’s Correspondence
`Address of Record for U.S. Patent No.
`10,889,858
`
`
`
`
`
`
`
`Dated: June 7, 2022
`1100 New York Avenue, NW
`Washington, DC 20005
`(202) 371-2600
`
`
`
`
`
`
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`/R. Wilson Powers III/
`
`Ralph Wilson Powers III, Ph.D.
`Registration No. 63,504
`Lead Attorney for Patent Owner
`
`
`
`
`
`
`
`
`
`
`
`
`